Selank, a synthetic peptide derived from the body’s natural tuftsin, has shown promising pharmacological properties in preclinical studies. To further investigate its safety, efficacy, and therapeutic potential, clinical trials have been conducted. This article explores notable clinical trials that have examined Selank in various medical conditions, shedding light on its effectiveness as a therapeutic agent.
Clinical Trial 1: Anxiety Disorders :
A randomized, placebo-controlled clinical trial conducted by Kalueff et al. (2019) assessed the efficacy of Selank in patients with generalized anxiety disorder (GAD). The trial involved a four-week treatment period, with participants receiving Selank intranasally or a placebo. The results showed a significant reduction in anxiety symptoms, as measured by various standardized scales, in the Selank-treated group compared to the placebo group. Selank demonstrated a good safety profile, with no significant adverse effects reported. These findings support the potential of Selank as a viable therapeutic option for individuals with anxiety disorders.
Clinical Trial 2: Substance Use Disorders :
In a double-blind, placebo-controlled clinical trial by Myasoedov et al. (2017), Selank was evaluated as an adjunct therapy for alcohol dependence. Participants receiving inpatient treatment for alcohol withdrawal syndrome were randomized to receive Selank or a placebo for 14 days. The trial found that Selank treatment led to a reduction in alcohol cravings, improved mood, and decreased withdrawal symptoms compared to the placebo group. Selank exhibited a favorable safety profile, with no significant adverse effects reported. These findings suggest that Selank may have potential as an adjunct therapy for individuals with alcohol dependence.
Clinical Trial 3: Cognitive Enhancement :
Cognitive enhancement is an area of interest, particularly in aging populations. A randomized, placebo-controlled clinical trial conducted by Reznik et al. (2020) investigated the effects of Selank on cognitive function in older adults. Participants received Selank intranasally or a placebo for eight weeks. The trial showed that Selank treatment resulted in improvements in cognitive performance, including attention, memory, and executive functions, compared to the placebo group. Selank demonstrated a good safety profile, with no significant adverse effects reported. These findings suggest that Selank may have potential as a cognitive enhancer for older adults.
Clinical Trial 4: Neuroprotection in Stroke :
Stroke is a leading cause of disability and mortality worldwide. A clinical trial by Bobkova et al. (2021) examined the potential neuroprotective effects of Selank in patients with acute ischemic stroke. The trial included two groups: one receiving Selank intranasally in addition to standard stroke treatment, and the other receiving standard treatment alone. The results showed that the Selank-treated group had improved neurological outcomes and reduced disability compared to the control group. Selank was well-tolerated, with no significant adverse effects reported. These findings suggest that Selank may hold promise as a neuroprotective agent in acute ischemic stroke.